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Carboxylesterase 1 (CES1) has recently been suggested to play a role in lipolysis. Our aim was to study the
regulation of CES1 expression in human adipose tissue. In the SOS Sib Pair Study, CES1 expression was
higher in obese compared with lean sisters (n = 78 pairs, P = 8.7  1018) and brothers (n = 12 pairs,
P = 0.048). CES1 expression was higher in subcutaneous compared with omental adipose tissue in lean
(P = 0.027) and obese subjects (P = 0.00036), and reduced during diet-induced weight loss (n = 24, weeks
8, 16, and 18 compared to baseline, P < 0.0001 for all time points). CES1 expression was higher in isolated
adipocytes compared with intact adipose tissue (P = 0.0018) and higher in large compared with small adi-
pocytes (P = 4.1  106). Basal and stimulated lipolysis was not different in individuals with high, inter-
mediate, and low expression of CES1. Thus, CES1 expression was linked to body fat and adipocyte fat
content but not to lipolytic activity.
 2009 Elsevier Inc.Open access under CC BY license.Introduction
Obesity is associated with the development of metabolic syn-
drome, a major risk factor for cardiovascular morbidity andmortal-
ity [1]. Obesity treatment improves metabolic function [2] and
reduces overall mortality [3]. The negative energy balance during
a hypocaloric diet is known to profoundly modify adipocyte
metabolism, particularly the lipolytic pathway [4]. Lipolysis, the
process leading to breakdown of triglycerides into fatty acids and
glycerol, requires the activities of TG lipases, mainly hormone-sen-
sitive lipase (HSL) and adipose triglyceride lipase (ATGL) [5].
The mammalian CES genes are members of the serine esterase
family and the encoded proteins are localized in the endoplasmic
reticulum (ER) of many tissues. These enzymes efﬁciently catalyze
the hydrolysis of a variety of ester- and amide-containing chemi-
cals [6]. In the mouse, carboxylesterase 3 (CES3; also called triacyl-
glycerol hydrolase; TGH), the homolog of human CES1, is
responsible for a major fraction of adipose tissue lipolytic activity
in vitro [7], and it has also been suggested that CES1 is a TG lipase
in man [8], however evidence is lacking.
The aim of this study was to examine CES1 expression in human
adipose tissue in relation to obesity, weight loss, adipocyte size,
adipose tissue location, and lipolysis.Jernås).
Y license.Materials and methods
All study subjects received written and oral information before
giving written informed consent. The regional Ethics Committee in
Gothenburg, at the Karolinska University Hospital and the South
Birmingham Ethics Committee approved these studies. Blood sam-
ples and adipose tissue biopsies were taken after an overnight fast.
Biochemical and anthropometrical measurements and examina-
tions were performed as described [9,10]. Computerized tomogra-
phy (CT) was used to determine body composition as previously
described [11].
Subjects and samples
Very low calorie diet (VLCD) studies. Twenty-four unrelated obese
subjects, 6 women and 18 men, were given VLCD (450 kcal/day) for
16 weeks followed by gradual reintroduction of a normal diet.
Abdominal subcutaneous adipose tissue biopsies and fasting blood
samples were obtained before (week 0), during (weeks 8 and 16),
and after (week 18) treatment. On average, the patients lost 27.7 kg
during the diet [12]. Microarray analysis was performed individually
in all 24 subjects at all time points. For veriﬁcation by real-time PCR,
abdominal subcutaneous adipose tissue biopsieswere obtained from
10 additional subjects at baseline, after 8 and 18 weeks of VLCD.
The SOS Sib Pair Study. The SOS Sib Pair Study consists of 154nucle-
ar families with BMI-discordant sib pairs (BMI differenceP
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Microarray expression analysis was performed in the offspring co-
hort. Normalizationwas performed usingMAS 5.0 (Affymetrix, Santa
Clara, CA). For correlations, results from 357 microarrays were in-
cluded. However, for comparisons between lean and obese siblings,
genderdiscordantpairswereexcludedandonly themostBMI-discor-
dant sib pair in each family was included, resulting in 78 pairs of sis-
ters and 12 pairs of brothers.
Paired abdominal subcutaneous and omental adipose tissue. Paired
abdominal subcutaneous and omental (n = 10) adipose tissue was
collected from female patients (age 45.4 ± 9.2 years; mean ± SD)
undergoing elective surgery (liposuction and elective gynecologi-
cal procedures), in accordance with guidelines of the South Bir-
mingham Ethics Committee. Smokers and subjects with recent
weight change, hormone replacement, and malignant diseases
were excluded. The subjects were divided into two groups accord-
ing to BMI (lean, BMI 23.0 ± 1.2 kg/m2; obese, BMI 33.2 ± 3.1 kg/
m2; mean ± SE). Microarray analysis was performed individually
on samples from all 10 subjects.
Large and small adipocytes. Needle biopsies of subcutaneous
abdominal adipose tissue were obtained from 3 (microarray anal-
ysis) and 5 healthy volunteers (real-time PCR analysis), and small
and large adipocytes were isolated as previously described [13].Fig. 1. Regulation of CES1 expression in human adipose tissue. (A) Adipose tissue CES1
(n = 24). (B) Adipose tissue CES1 expression during diet-induced weight loss measured
siblings (12 pairs of brothers and 78 pairs of sisters) measured by DNAmicroarray analysi
5 obese and 5 lean women measured by DNA microarray analysis. (E) CES1 expressionIsolated adipocytes and intact adipose tissue. Subcutaneous abdom-
inal adipose tissuebiopsieswere obtainedby needle aspirations in14
subjects. A fraction was immediately frozen at 70 C, and from the
remaining adipose tissue, adipocytes were isolated by collagenase
digestion [14]. RNA was prepared and real-time PCR analysis was
performed on isolated adipocytes and intact adipose tissue.
Studies of lipolysis. Subcutaneous abdominal adipose tissue
biopsies were obtained by needle aspirations in 81 obese women
under local anesthesia (BMI 31–53 kg/m2 and age 21–63 years). A
fraction (300 mg) was immediately frozen at 70 C and used for
subsequent mRNA analysis, and the remaining tissue was used
for lipolysis studies. The lipolysis assay has previously been de-
scribed in detail [15]. In brief, a diluted suspension of isolated fat
cells (about 5000–10,000 cells/ml) was incubated for 2 h in dupli-
cate with air as the gas phase at 37 C in Krebs–Ringer phosphate
buffer (pH 7.4) supplemented with glucose (8.6 lmol/ml), ascorbic
acid (0.1 mg/ml), and bovine serum albumin (20 mg/ml) in the
absence (basal) or presence of increasing concentrations noradren-
aline (a non-selective b- and a2-adrenoreceptor agonist) or insulin.
8-Bromo-cyclic AMP (1 mmol/l, phosphodiesterase non-resistant
cyclic AMP analogue) was added in the insulin experiments in or-
der to magnify the antilipolytic effect of insulin. After the incuba-
tion, glycerol was measured in the media (lipolysis index) usingexpression during diet-induced weight loss measured by DNA microarray analysis
by real-time PCR (n = 10). (C) CES1 expression in adipose tissue of obese and lean
s. (D) CES1 expression in paired abdominal and omental adipose tissue samples from
in isolated small and large adipocytes measured by real-time PCR (n = 5).
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as lmol glycerol per 107 cells per 2 h. Basal and 8-bromo-cyclic
AMP-affected glycerol release and the glycerol release at the max-
imum effective concentration for noradrenaline and insulin were
calculated.
RNA preparation and DNA microarray analysis
Total RNA from adipose tissue was prepared with Qiagen Lipid
tissue kit (Qiagen, Hilden, Germany). Total RNA from adipocytes
was prepared with the phenol–chloroform extraction method of
Chomczynski and Sacchi [16]. After further puriﬁcationwith RNeasy
(Qiagen), the RNA concentration wasmeasured spectrophotometri-
cally. The A260/A280 ratio was 1.8–2.0 and the quality of the RNAwas
veriﬁed by agarose gel electrophoresis before reverse transcription
into cDNA. Gene expression was measured using the Human Gen-
ome U133A or U133Plus2.0 DNA microarray (Affymetrix). Prepara-
tion of cRNA and hybridization was performed according to
standard Affymetrix protocols as previously described [9].
Real-time PCR analysis of gene expression
Reagents for real-time PCR analysis of CES1 and the reference
genes LDL receptor-related protein 10 (LRP10) and 18S rRNA (As-
says-on-Demand, TaqMan Reverse Transcriptase reagents, and
TaqMan Universal PCR Master Mix) were from Applied Biosystems
(Foster City, CA) and used according to the manufacturer’s proto-
col. cDNA corresponding to 10 ng of RNA per reaction was used
for real-time PCR analysis. Speciﬁc products were ampliﬁed and
detected with the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems) using default cycle parameters. A standard
curve obtained by serial dilution of pooled adipocyte cDNA was
plotted for each primer–probe set. All standards and samples were
analyzed in triplicate.
Statistical analysis
Correlations between CES1 expression and anthropometric and
biochemical markers were performed using the Spearman rankTable 1
Characteristics of the patients included in the VLCT study and association of CES1 express
parameters during diet-induced weight loss.
Week 0 Week 8
BMI (kg/m2) 37.6 ± 4.9 31.8 ± 4.1
Waist (cm) 123 ± 12 110 ± 12
WHR 1.02 ± 0.08 0.99 ± 0.08
TAT (cm2) 778 ± 191
SAT (cm2) 526 ± 166
VAT (cm2) 241 ± 76
S-BP (mmHg) 138 ± 17 121 ± 12
D-BP (mmHg) 88 ± 13 76 ± 11
F-glucose (mmol/L) 6.0 ± 1.6 4.5 ± 0.7
OGTT glucose (mmol/L) 8.2 ± 3.8 7.0 ± 1.9
F-insulin (mU/L) 15.8 ± 7.4 7.0 ± 4.1
OGTT insulin (mU/L) 67 ± 43 41 ± 21
HOMA 4.4 ± 2.7 1.4 ± 0.9
Total C (mmol/L) 5.6 ± 0.2 3.9 ± 0.1
LDL-C (mmol/L) 3.6 ± 1.0 2.3 ± 0.8
HDL-C (mmol/L) 1.4 ± 0.4 1.2 ± 0.3
TG (mmol/L) 1.8 ± 1.0 1.0 ± 0.2
hs-CRP (mg/L) 5.3 ± 5.8 4.6 ± 5.4
Leptin (ng/L) 35.6 ± 3.2 8.6 ± 1.2
Adiponectin (lg/ml) 8.2 ± 0.8 10.4 ± 1.1
BMI, body mass index; WHR; waist hip ratio; TAT, total adipose tissue; SAT, subcutaneo
diastolic blood pressure; F-glucose, fasting plasma glucose; C, cholesterol; LDL, low densi
C-reactive protein, n = 24. The clinical characteristics of subjects in the VLCD study havecorrelation test. Differences in gene expression between cell popu-
lations were analyzed using the Wilcoxon signed-rank test. Differ-
ences in CES1 expression between lean and obese siblings were
assessed using a paired T-test. Correlation of within person longi-
tudinal measurements for the overall relations across the entire
VLCD study duration was addressed through the use of generalized
estimating equations [17], as previously described [12]. Values are
expressed as mean ± SD.Results
Diet-induced weight loss
DNA microarray analysis showed that CES1 expression was re-
duced in subcutaneous adipose tissue after 8 and 16 weeks of VLCD
compared with baseline (P < 0.0001 and P < 0.0001, respectively,
Fig. 1A). CES1 expression remained signiﬁcantly reduced compared
with baseline also after the 2 weeks of reintroduction to normal
food (week 18; P < 0.0001; Fig. 1A). The reduced CES1 expression
at weeks 8 and 18 compared to baseline was veriﬁed by real-time
PCR in another 10 subjects treated with VLCD (P = 0.032 and
P = 0.0057, respectively, Fig. 1B).
CES1 expression levels in the VLCD study correlated with sev-
eral anthropometric and biochemical parameters, including total
adipose tissue, subcutaneous adipose tissue, OGTT insulin, choles-
terol, low density lipoprotein cholesterol (LDL-C), and high density
lipoprotein cholesterol (HDL-C) (Table 1).
Obesity-discordant siblings
In the SOS Sib Pair Study, obese females and males displayed
higher CES1 expression compared with their lean siblings of the
same gender (females P = 8.7  1018 and males P = 0.048;
Fig. 1C). CES1 expression levels correlated with several anthro-
pometric and biochemical parameters, including BMI, waist,
waist hip ratio, systolic blood pressure, diastolic blood pressure,
OGTT, F-insulin, HOMA, cholesterol, LDL-C, HDL-C, and hs-CRP
(Table 2).ion, analyzed by DNA microarray, with anthropometric measurements and metabolic
CES1
Week 16 Week 18 Slope P-value
28.6 ± 4.1 28.9 ± 3.9 0.067 0.30
101 ± 13 101 ± 13 0.051 0.51
0.95 ± 0.08 0.95 ± 0.08 0.26 0.060
419 ± 174 0.056 0.016
311 ± 137 0.057 0.0062
101 ± 49 0.14 0.46
117 ± 14 124 ± 16 0.056 0.44
72 ± 11 76 ± 12 0.089 0.063
4.5 ± 0.7 5.0 ± 1.0 0.51 0.26
7.0 ± 2.6 5.9 ± 2.3 0.58 0.056
4.3 ± 2.2 6.3 ± 3.7 0.37 0.081
34 ± 17 24 ± 10 0.46 0.0051
0.9 ± 0.5 1.5 ± 1.3 0.31 0.066
4.4 ± 0.1 4.8 ± 0.1 2.05 0.0054
2.6 ± 0.6 2.9 ± 0.7 0.068 0.041
1.4 ± 0.4 1.4 ± 0.3 1.28 0.046
0.9 ± 0.2 1.2 ± 0.5 0.21 0.53
2.4 ± 1.5 2.4 ± 2.2 0.10 0.53
5.3 ± 0.9 7.6 ± 1.1 0.047 <0.0001
12.5 ± 1.05 14.1 ± 1.3 0.50 0.12
us adipose tissue; VAT, visceral adipose tissue; S-BP, systolic blood pressure; D-BP,
ty lipoprotein; HD, high density lipoprotein; TG, triglyceride; hs-CRP, high sensitive
been described before [10,12,25,26].
Table 2
Correlations between adipose tissue CES1 expression and anthropometric and
biochemical parameters in the SOS Sib Pair Study.
CES1
P-value r
BMI (kg/m2) 29.6 ± 8.2 <0.0001 0.66
Waist (cm) 95.9 ± 19.3 <0.0001 0.63
WHR 0.9 ± 0.09 <0.0001 0.45
S-BP (mmHg) 118 ± 15 <0.0001 0.22
D-BP (mmHg) 72 ± 11 <0.0001 0.24
F-glucose (mmol/L) 5.0 ± 1.1 0.28 0.057
F-insulin (mU/L) 9.6 ± 7.6 <0.0001 0.54
HOMA 2.2 ± 2.1 <0.0001 0.51
Total-C (mmol/L) 4.4 ± 0.9 0.0446 0.077
LDL-C (mmol/L) 2.7 ± 0.7 <0.0001 0.18
HDL-C (mmol/L) 1.2 ± 0.3 <0.0001 0.38
TG (mmol/L) 1.1 ± 0.7 <0.0001 0.37
hs-CRP (mg/L) 4.3 ± 6.3 <0.0001 0.50
BMI, body mass index; WHR, waist hip ratio; S-BP, systolic blood pressure; D-BP,
diastolic blood pressure; F-glucose, fasting plasma glucose; C, cholesterol; LDL, low
density lipoprotein; HDL, high density lipoprotein; TG, triglyceride; hs-CRP, high
sensitive C-reactive protein, n = 357.
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CES1 expression was higher in isolated adipocytes compared
with intact adipose tissue (P = 0.0018) and higher in subcutaneous
compared with omental adipose tissue in both obese and lean sub-
jects (obese, P = 0.00036; lean, P = 0.027; Fig. 1D). Moreover, CES1
expressionwashigher in large comparedwith small adipocytes from
the same biopsy measured by DNAmicroarray (P = 4.1  106), and
this was veriﬁed with real-time PCR (P = 0.046, Fig. 1E).
CES1 expression in relation to lipolysis
To examine the relation between CES1 expression and lipolysis,
adipocytes from different individuals were divided into tertilesFig. 2. Relation between CES1 expression and lipolysis in isolated adipocytes. Basal lipoly
(C), and 8b-cAMP + insulin-inhibited lipolysis (D) in samples with high, intermediate, anbased on their relative CES1 expression measured by real-time
PCR. There were no differences in either basal or 8b-cAMP-medi-
ated lipolysis between samples with low, intermediate, and high
CES1 expression. Moreover, both noradrenaline-stimulated and
insulin-inhibited lipolysis was similar in samples with high, inter-
mediate, and low expression levels of CES1 mRNA (Fig. 2A–D).
Discussion
In this study, we investigated the regulation of CES1 expression
in human adipose tissue and the relation between CES1 expression
and TG lipolysis in adipocytes. Our results show that the expres-
sion of the CES1 gene is highly regulated in human adipose tissue,
with increased levels in obese subjects and decreased levels during
weight loss. However, there was no association between CES1
expression and lipolysis in isolated human adipocytes.
In our study, CES1 expression was markedly higher in adipose
tissue from obese compared to lean subjects, which is in accor-
dance with the results reported by Steinberg et al. [8]. In obese
subjects, diet-induced weight loss resulted in decreased CES1
expression. During the VLCD study, CES1 expression correlated
with total and subcutaneous adipose tissue mass measured by
CT. CES expression was higher in adipocytes compared to whole
adipose tissue, suggesting that the adipocyte is the main site of
CES1 expression in adipose tissue. In addition, large adipocytes
have higher CES1 expression compared with small adipocytes. Ta-
ken together, our results indicate that adipose tissue expression of
CES1 is tightly linked to obesity, amount of body fat, and adipocyte
fat content.
It has been suggested that CES3, the mouse homolog of human
CES1, plays a major role in stimulated and basal lipolysis in mice
[7]. To clarify the role of CES1 in human adipose tissue we analyzed
basal, stimulated and inhibited lipolysis in isolated human adipo-
cytes and found no differences in samples with low, intermediate,
and high CES1 expression. Since differences in CES1 expression
were not accompanied by differences in lipolytic activity our datasis (A), maximal noradrenaline-stimulated lipolysis (B), 8b-cAMP-mediated lipolysis
d low CES1 mRNA levels measured by real-time PCR.
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tant lipase in human adipose tissue. Schweiger et al. recently dem-
onstrated that 95% of the lipolysis in adipose tissue in mice is
mediated via ATGL and HSL [18], thereby also questioning the
importance of other lipases such as CES1. Studies on the main li-
pases, HSL and ATGL, show that their regulation in human adipose
tissue differs from the regulation of CES1. HSL expression is re-
duced in obesity [19–22] and the expression is increased after
weight reduction [19]. ATGL expression on the other hand is not
different in adipose tissue from obese compared to lean subjects
and it is not affected by weight reduction [19]. In both the VLCD
study and in the Sib Pair Study, CES1 expression in adipose tissue
correlated with metabolic parameters, including total cholesterol,
LDL-C, and HDL-C. Interestingly, it has been suggested that CES1,
addition to its proposed lipolytic activities, also affects a variety
of endogenous cholesterol metabolism pathways, including choles-
terol esteriﬁcation and hydrolyzation of cholesterol esters [23,24].
However, further studies are needed to determine if the associa-
tions between CES1 expression and plasma lipid levels are linked
to effects of CES1 on cholesterol metabolism.
We conclude that the expression of CES1 is associated with
body fat and adipocyte fat content. However, CES1 expression
was not associated with the lipolytic activity in isolated adipo-
cytes. Taken together, our data show that increased CES1 expres-
sion is associated with obesity and markers of metabolic
dysfunction indicating that CES1 plays a role in human metabo-
lism, however, the mechanisms are unclear.
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